File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Association between prenatal antipsychotic exposure and the risk of attention-deficit/hyperactivity disorder and autism spectrum disorder: a systematic review and meta-analysis

TitleAssociation between prenatal antipsychotic exposure and the risk of attention-deficit/hyperactivity disorder and autism spectrum disorder: a systematic review and meta-analysis
Authors
KeywordsAntipsychotic
Attention-deficit/hyperactivity disorder
Autism spectrum disorder
Pregnancy
Issue Date1-May-2024
PublisherElsevier
Citation
Neuroscience & Biobehavioral Reviews, 2024, v. 160 How to Cite?
AbstractThe paucity of evidence regarding the safety of gestational antipsychotic exposure has led to treatment discontinuation in pregnant women with severe mental health conditions. This systematic review and meta-analysis aimed to summarise the current evidence on the association between gestational antipsychotic exposure and attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in children (Study protocol registered in PROSPERO:CRD42022311354). Five studies included in our meta-analysis with around 8.6 million pregnancy episodes in nine different countries/regions. Results from our meta-analysis indicate that the heightened risks of ASD and ADHD in children gestationally exposed to antipsychotics appear to be attributable to maternal characteristics, rather than having a causal relationship with the antipsychotic exposure during pregnancy. The results underscore the importance of meticulously monitoring the neurodevelopment of children born to mothers with mental illnesses, which can facilitate early interventions and provide requisite support.
Persistent Identifierhttp://hdl.handle.net/10722/346378
ISSN
2023 Impact Factor: 7.5
2023 SCImago Journal Rankings: 2.810

 

DC FieldValueLanguage
dc.contributor.authorWang, Zixuan-
dc.contributor.authorYuen, Andrew SC-
dc.contributor.authorWong, Kirstie HTW-
dc.contributor.authorChan, Adrienne YL-
dc.contributor.authorCoghill, David-
dc.contributor.authorSimonoff, Emily-
dc.contributor.authorLau, Wallis CY-
dc.contributor.authorWong, Ian CK-
dc.contributor.authorPark, Sohee-
dc.contributor.authorMan, Kenneth KC-
dc.date.accessioned2024-09-16T00:30:31Z-
dc.date.available2024-09-16T00:30:31Z-
dc.date.issued2024-05-01-
dc.identifier.citationNeuroscience & Biobehavioral Reviews, 2024, v. 160-
dc.identifier.issn0149-7634-
dc.identifier.urihttp://hdl.handle.net/10722/346378-
dc.description.abstractThe paucity of evidence regarding the safety of gestational antipsychotic exposure has led to treatment discontinuation in pregnant women with severe mental health conditions. This systematic review and meta-analysis aimed to summarise the current evidence on the association between gestational antipsychotic exposure and attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in children (Study protocol registered in PROSPERO:CRD42022311354). Five studies included in our meta-analysis with around 8.6 million pregnancy episodes in nine different countries/regions. Results from our meta-analysis indicate that the heightened risks of ASD and ADHD in children gestationally exposed to antipsychotics appear to be attributable to maternal characteristics, rather than having a causal relationship with the antipsychotic exposure during pregnancy. The results underscore the importance of meticulously monitoring the neurodevelopment of children born to mothers with mental illnesses, which can facilitate early interventions and provide requisite support.-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofNeuroscience & Biobehavioral Reviews-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAntipsychotic-
dc.subjectAttention-deficit/hyperactivity disorder-
dc.subjectAutism spectrum disorder-
dc.subjectPregnancy-
dc.titleAssociation between prenatal antipsychotic exposure and the risk of attention-deficit/hyperactivity disorder and autism spectrum disorder: a systematic review and meta-analysis-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.neubiorev.2024.105635-
dc.identifier.pmid38499117-
dc.identifier.scopuseid_2-s2.0-85188067116-
dc.identifier.volume160-
dc.identifier.issnl0149-7634-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats